Market Overview

Covidien Launches OneShot Renal Denervation System

Covidien
(NYSE: COV) today announced the commercial launch of the OneShotâ„¢ Renal Denervation
System, an over the wire balloon-based irrigated catheter technology for
the treatment of high blood pressure or hypertension.

Covidien today announced the commercial launch of the OneShot Renal Denervation System, an over the wire balloon-based irrigated catheter technology for the treatment of high blood pressure. (Photo: Business Wire)

Placed percutaneous, OneShot delivers radiofrequency (RF) energy in a
circumferential manner to the renal arterial wall, and requires only a
single treatment per artery. OneShot received the CE Mark in February
2012 and has been undergoing clinical trial evaluation in New Zealand
and Europe. The product will be rolled out in Europe, Middle

See full press release

Posted-In: Earnings News Guidance Management Global

 

Most Popular

Related Articles (COV)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters